IPTLD® a Registered Trademark by Donato Perez Garcia
Paseo de los Heroes # 10999 - 607
Tijuana, B.C. 22010 México
Phone:
From US: 011-52-(664)-686-5473
From US: 011-52-(664)-635-1834
Email: drdonato3@iptldmd.com
Join us at:
Copyright © 1930 – 2010 Donato Perez Garcia
¿ How IPTLD ® Works ?
Insulin Potentiation Targeted Low Dose therapy (IPTLD ®) manipulates the mechanisms of malignancy to therapeutic advantage by employing insulin as a biologic response modifier of cancer cells endogenous molecular biology. The autonomous proliferation of malignancy is supported by autocrine secretion of insulin for glucose/energy uptake by cancer cells, and a similar autocrine and/or paracrine elaboration of cellular factors to stimulate cancer growth. Amongst these, the insulin-like growth factors have been identified as the most potent mitogens for cancer cells. Of primary importance for IPTLD ®, cancer cell membranes also have six times more insulin receptors and ten times more IGF receptors, per cell, than the membranes of host normal tissues. Further, insulin can cross-react with and activate cancer cell IGF receptors. Thus, per cell, cancer has sixteen times more insulin-sensitive receptors than normal tissues. As ligand effect is a function of receptor concentration, these facts serve to differentiate cancer from normal cells - a vital consideration for the safety of cancer chemotherapy.
In light of these revelations, exogenous insulin acts to enhance anticancer drug cytotoxicity, and safety, via:
1) a membrane permeability effect to increase the intracellular dose intensity of the drugs;
2) an effect of metabolic modification to increase the S-phase fraction in cancer cells, enhancing their susceptibility to cell-cycle phase-specific agents, and;
3) an effect of biochemical differentiation based on insulin receptor concentration that focuses the first two insulin effects predominantly on cancer cells, sparing host normal tissues.
Significantly less drug can thus be targeted more specifically and more effectively to cancer cell populations that are more susceptible to the chemotherapy drug effects, all this occurring with a virtual elimination of the dose-related side effects of these powerful drugs.
Because of this favorable side effect profile, cycles of low-dose chemotherapy with IPTLD ® may be done more frequently. There is good patient acceptance of the hypoglycemic side effect of insulin in this protocol, and the "rescue phenomenon" occasioned by the timely administration of hypertonic glucose actually serves to provide patients with an experiential metaphor for the rapid recovery of their well being. It is acknowledged that cancer treatment can often be debilitating for patients. In those undergoing treatment with IPTLD ®, an overall gentler experience promotes their concurrent use of other important elements in a program of Comprehensive Cancer Care, as administered at my office.
The History of IPTLD
By: Donato Perez Garcia III,MD
IPT or IPTLD ® has been in existence as a therapy since 1930 and has been used successfully as a treatment for cancer since January of 1946. Insulin Potentiation Therapy (IPT) was initially developed in 1930 for the treatment of human disease by Donato Perez Garcia, Sr. MD (1896-1971). A surgeon lieutenant in the Mexican military establishment, his preliminary work with insulin involved an innovative course of self-treatment for a gastrointestinal problem that he suffered from for years. All previous treatments had failed to resolve it.
When he first learned of the then newly discovered hormone insulin being used to treat diabetes, he noted that, in addition to diabetes, its use was also indicated for the treatment of non-diabetic malnutrition. So he decided to try it on himself. The treatment was completely successful; his symptoms disappeared and his weight became normal.
Reflecting on his own experience, Dr. Perez Garcia did what many innovators in the medical field do. He asked himself "why?" He considered that the insulin might have helped his body tissues assimilate the food he had eaten and wondered if perhaps insulin might help tissues assimilate medications. Over the years Dr.Perez Garcia treated several diseases. With his son, Donato Perez Garcia II MD (1930-2000) they did animal experiments to demonstrate the changes produced by insulin on the contenents of the human blood and his grandson, Donato Perez Garcia III (1958 - ) after the year 2001, I started a training workshop program to teach interested medical doctors on IPT. The name IPT was recently changed to Insulin Potentiation Targeted Low Dose (IPTLD ®) to more accurately reflect its unique cancer-fighting methodology.
The Various Names of IPTLD
The various names of the IPT therapies evolved as the treatment itself evolved.
1928-1971
The first period begins with the discovery in 1928 untill 1971.This was the period where the inventor, the medical doctor Donato Perez Garcia, called his treatment "Cellular Therapy" and this name according to my grandfather, described in simple terms his theory: that insulin helped to deliver the prescription drugs inside the cell where they will correct the disease and also it produced a change in the physical and chemical reactions that occurred in the blood to restore balance and maintain the state of good health. He began to use this name since 1930. In the year of 1955 my father joined him and he continued using the same name and following the treatment routine without any modifications. Insulin, which was made from the pancreas of pigs was administered intramuscularly to patients. Because the substance was a protein it could not be administered intravenously due to the risk of an allergic reaction. The first patient treated succesfully for cancer was a woman with breast cancer treated by my grandfather in 1946.
1971-1982
The second period began after my grandfather’s death on December 12 of 1971 until 1982. My father continued administering the treatment the same way he learned from his father. Even two of the nurses that worked for my grandfather continued with my father, as they knew the routine. In 1974 my father began to use the name "Donatian Therapy" to his adaptation of the treatment and these were the modifications he introduced:
1- A cleansing enema prior to the treatment using flax seed and leafs of senna boiled in water.
2-
A nasal administration of oxygen during the procedure.
3-
He developed some formulas of his own to treat some cancers and one was a vaginal insert to treat cervical cancer in women in which he mixed several substances. This vaginal insert was placed after the patient had emptied her bowels.
1982-Present
In the third period I began to learn the treatment with my father in March of 1982, always by his side and learning the routine that he learned from his father. I was seated by his side at his desk and took notes, and he asked for my opinion on each of the patients we saw for consultation. By December of 1982, I introduced the intravenous use of insulin to patients receiving the treatment. Later that month the first modification of the administration procedure was in place and patients began with the new routine. After January of 1983 the name continued to be Cellular therapy or Donatian therapy or simply “ the treatment.”
A simple modification took place after receiving a phone call in the year of 1984 from Steven Ayre, MD. Dr. Ayre was writing a protocol to be presented to the NIH and he required to have dosages, names of substances, why they were prescribed and for what conditions. I tried to make simple the procedure he learned in 1975 from my father which used several drugs and an enema. Since this was a big project and the idea was to make the treatment easy for the NIH medical doctors, I worked to design a treatment that was simple and easy to administer. When I completed the job of having a simple method of administration for the treatment that could be easily administered, the name Dr.Ayre considered appropriate was Insulin Potentiation Therapy or IPT. This new name was introduced in the year of 1986 and the first scientific article about the IPT treatment was published. My father was not pleased with the new name and he never used the new name in his daily private practice. In any event I was the creator of this modification and I was working with Dr. Ayre to bring this treatment to the public. I went ahead and began training medical doctors on the modified treatment. The first one was Dr. Ayre in 1997 and then I trained more medical doctors in February of 2001 during the First training workshop held in a Conference in Las Vegas, NV with a group of 21 MD's from the USA and Canada. After this date I went ahead with the training workshops and have now trained more than 300 physicians from 27 countries.
Today (October 2009) the name of this therapy is “Insulin Potentiation Targeted Low Dose or IPTLD ®” and it is comprised of a combination of the best protocols developed by the Donato’s. The name IPTLD ® is now a Trademark.